23
december 2020
alphamab oncology announced that the u.s. food and drug administration (fda) has granted orphan drug designation to the combination therapy of kn026 plus kn046 for the treatment of gastric cancer, including cancer of the gastroesophageal junction
this is the third odd granted to alphamab oncology by fda.
